# US 2018/0022714 A1 · Certain chemical entities, compositions, and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022714 A1
- Document ID: US20180022714A1
- Status: Published application
- Kind: A1
- Application number: 15/617,505
- Filed: 2017-06-08
- Published: 2018-01-25
- Earliest claimed: 2012-11-12
- Assignees: Neupharma, Inc.
- Applicants: Neupharma, Inc.
- Inventors: Xiangping QIAN; Yong-liang ZHU
- Web page: https://patentgrep.com/patent/US20180022714A1

## CPC

- C07D 241/44: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

## Claims

### Claim at position 1

-45. (canceled)

### Claim 46

A method of inhibiting KDR kinase activity in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1, R2, R3, R4, R5, R6, R7, R8, and R10 are independently hydrogen, cyano, halo, hydroxy, azido, nitro, carboxy, sulfinyl, sulfanyl, sulfonyl, alkoxy, cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, alkyl, alkenyl, aryl, heteroaryl, heterocycloalkyl, amino, acyl, alkoxycarbonyl, aminocarbonyl, aminosulfonyl, carbamimidoyl, or alkynyl;
R9 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R11 is hydroxy, formyl, alkoxy, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —COR12, —CO2R12, —CONR12R13, —C(NR14)NR12R13, —C(NCN)NR12R13, or —SO2NR12R13; or
R9 and R11 may be joined together with any intervening atoms to form a heterocycloalkyl ring;
R12 is alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R13 and R14 are independently hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or
R12 and R13 may be joined together with any intervening atoms to form a heterocycloalkyl ring;
wherein:
any of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, the heterocycloalkyl ring formed by R9 and R11, and the heterocycloalkyl ring formed by R12 and R13 may be substituted with one or more substituents independently selected from the group consisting of C1-C4 alkyl, aryl, heteroaryl, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl, —OC1-C4 alkyl, —OC1-C4 alkylphenyl, —C1-C4 alkyl-OH, —OC1-C4 haloalkyl, halo, —OH, —NH2, —C1-C4 alkyl-NH2, —N(C1-C4 alkyl)(C1-C4 alkyl), —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkylphenyl), —NH(C1-C4 alkylphenyl), cyano, nitro, oxo, —CO2H, —C(O)OC1-C4 alkyl, —CON(C1-C4 alkyl)(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CONH2, —NHC(O)(C1-C4 alkyl), —NHC(O)(phenyl), —N(C1-C4 alkyl)C(O)(C1-C4 alkyl), —N(C1-C4 alkyl)C(O)(phenyl), —C(O)C1-C4 alkyl, —C(O)C1-C4 alkylphenyl, —C(O)C1-C4 haloalkyl, —OC(O)C1-C4 alkyl, —SO2(C1-C4 alkyl), —SO2(phenyl), —SO2(C1-C4 haloalkyl), —SO2NH2, —SO2NH(C1-C4 alkyl), —SO2NH(phenyl), —NHSO2(C1-C4 alkyl), —NHSO2(phenyl), and —NHSO2(C1-C4 haloalkyl).

### Claim 47 (depends on 46)

The method of claim 46, wherein R1 is hydrogen, cyano, halo, hydroxy, carboxy, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkoxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted amino, optionally substituted acyl, optionally substituted alkoxycarbonyl, optionally substituted aminocarbonyl, optionally substituted aminosulfonyl, optionally substituted carbamimidoyl, or optionally substituted alkynyl.

### Claim 48 (depends on 46)

The method of claim 46, wherein R1 is optionally substituted aryl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl.

### Claim 49 (depends on 46)

The method of claim 46, wherein R1 is optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, or optionally substituted pyridyl.

### Claim 50 (depends on 46)

The method of claim 46, wherein R2, R3, R4, and R5 are independently hydrogen, halo, cyano, optionally substituted alkoxy, or optionally substituted alkyl.

### Claim 51 (depends on 46)

The method of claim 46, wherein R2, R3, R4, and R5 are independently hydrogen or halo.

### Claim 52 (depends on 46)

The method of claim 46, wherein R6, R7, R8, and R10 are independently hydrogen, cyano, halo, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted acyl, optionally substituted alkoxycarbonyl, optionally substituted aminocarbonyl, or optionally substituted aminosulfonyl.

### Claim 53 (depends on 46)

The method of claim 46, wherein R6, R7, R8, and R10 are independently hydrogen, cyano, or halo.

### Claim 54 (depends on 46)

The method of claim 46, wherein R9 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 55 (depends on 46)

The method of claim 46, wherein R9 is hydrogen or optionally substituted lower alkyl.

### Claim 56 (depends on 46)

The method of claim 46, wherein R11 is —COR12, —CO2R12, —CONR12R13, —C(NR14)NR12R13, —C(NCN)NR12R13, or —SO2NR12R13.

### Claim 57 (depends on 46)

The method of claim 46, wherein R12 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and R13 and R14, when present, are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.

### Claim 58 (depends on 46)

The method of claim 46, wherein R12 is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and R13 and R14, when present, are independently hydrogen or optionally substituted alkyl.

### Claim 59 (depends on 46)

The method of claim 46, wherein R12 is optionally substituted aryl.

### Claim 60 (depends on 46)

The method of claim 46, wherein R12 is optionally substituted heteroaryl.

### Claim 61 (depends on 46)

The method of claim 46, wherein R12 and R13, when present, are joined together with any intervening atoms to form an optionally substituted 4- to 8-membered heterocycloalkyl ring.

### Claim 62 (depends on 46)

The method of claim 46, wherein R9 and R11 are joined together with any intervening atoms to form an optionally substituted 4- to 8-membered heterocycloalkyl ring.

### Claim 63 (depends on 46)

The method of claim 46, wherein the subject suffers from a cancer selected from the group consisting of bladder, breast, colorectal, head and neck, liver, lung, skin, ovarian, pancreatic, prostate, renal, stomach, and thyroid cancer.

### Claim 64 (depends on 46)

The method of claim 46, wherein the subject suffers from a cancer selected from the group consisting of melanoma, non-small cell lung cancer, colon cancer, thyroid cancer, and ovarian cancer.

### Claim 65 (depends on 46)

The method of claim 46, further comprising administering to the subject an additional anti-cancer and/or cytotoxic agent.
